Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary.

Clark IA, Vissel B.

Expert Rev Neurother. 2019 Jun;19(6):535-543. doi: 10.1080/14737175.2019.1618710. Epub 2019 May 24.

PMID:
31092047
2.

Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study.

Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Kim AS, Johnson JN, Bates D, Poggio G, Case C, McGrogan M, Yankee EW, Schwartz NE.

J Neurosurg. 2018 Nov 23:1-11. doi: 10.3171/2018.5.JNS173147. [Epub ahead of print]

PMID:
30497166
3.

[Current status of development for regenerative cell therapy, SB623].

Kaneko T.

Nihon Yakurigaku Zasshi. 2018;151(3):117-121. doi: 10.1254/fpj.151.117. Japanese.

PMID:
29526920
4.

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms.

Stonesifer C, Corey S, Ghanekar S, Diamandis Z, Acosta SA, Borlongan CV.

Prog Neurobiol. 2017 Nov;158:94-131. doi: 10.1016/j.pneurobio.2017.07.004. Epub 2017 Jul 23. Review.

5.

Response by Steinberg et al to Letter Regarding Article, "Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2A Study".

Steinberg GK, Kondziolka D, Bates D; SB623 Stroke Phase 1/2A Study Group.

Stroke. 2016 Dec;47(12):e269. Epub 2016 Nov 15. No abstract available.

PMID:
27895304
6.

Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study.

Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, Kim AS, Johnson JN, Bates D, King B, Case C, McGrogan M, Yankee EW, Schwartz NE.

Stroke. 2016 Jul;47(7):1817-24. doi: 10.1161/STROKEAHA.116.012995. Epub 2016 Jun 2.

7.

Mesenchymal stromal SB623 cell implantation mitigates nigrostriatal dopaminergic damage in a mouse model of Parkinson's disease.

Tate CC, Chou VP, Campos C, Moalem AS, Di Monte DA, McGrogan M, Case CC, Manning-Bog AB.

J Tissue Eng Regen Med. 2017 Jun;11(6):1835-1843. doi: 10.1002/term.2081. Epub 2015 Oct 6.

PMID:
26440859
8.
9.

Comparing the angiogenic potency of naïve marrow stromal cells and Notch-transfected marrow stromal cells.

Dao M, Tate CC, McGrogan M, Case CC.

J Transl Med. 2013 Mar 27;11:81. doi: 10.1186/1479-5876-11-81.

10.

Comparing the immunosuppressive potency of naïve marrow stromal cells and Notch-transfected marrow stromal cells.

Dao MA, Tate CC, Aizman I, McGrogan M, Case CC.

J Neuroinflammation. 2011 Oct 7;8:133. doi: 10.1186/1742-2094-8-133.

11.

Glial cell line-derived neurotrophic factor-secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease.

Glavaski-Joksimovic A, Virag T, Mangatu TA, McGrogan M, Wang XS, Bohn MC.

J Neurosci Res. 2010 Sep;88(12):2669-81. doi: 10.1002/jnr.22435.

PMID:
20544825
12.

Human mesenchymal stromal cells and their derivative, SB623 cells, rescue neural cells via trophic support following in vitro ischemia.

Tate CC, Fonck C, McGrogan M, Case CC.

Cell Transplant. 2010;19(8):973-84. doi: 10.3727/096368910X494885. Epub 2010 Mar 26.

PMID:
20350349
13.

Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.

Glavaski-Joksimovic A, Virag T, Chang QA, West NC, Mangatu TA, McGrogan MP, Dugich-Djordjevic M, Bohn MC.

Cell Transplant. 2009;18(7):801-14. doi: 10.3727/096368909X470801. Epub 2009 Sep 28.

PMID:
19796495
14.

Extracellular matrix produced by bone marrow stromal cells and by their derivative, SB623 cells, supports neural cell growth.

Aizman I, Tate CC, McGrogan M, Case CC.

J Neurosci Res. 2009 Nov 1;87(14):3198-206. doi: 10.1002/jnr.22146.

PMID:
19530164

Supplemental Content

Loading ...
Support Center